Table 3.
Adverse events of grade 3 or worse
| Placebo (n=16) | AZD8931 (n=15)* | |
|---|---|---|
| Nausea | 0 | 0 |
| Vomiting | 0 | 0 |
| Diarrhoea | 1 (6%) | 1 (7%) |
| Stomatitis | 0 | 0 |
| Dry skin | 0 | 0 |
| Skin rash | 0 | 3 (20%) |
| Acne | 0 | 0 |
| PPE | 0 | 0 |
| Anaemia | 0 | 1 (7%) |
| Neutropenia | 0 | 0 |
| Thrombocytopenia | 0 | 0 |
| Hyperbilirubinaemia | 0 | 1 (7%) |
| Elevated ALT or AST | 0 | 0 |
| Hypomagnesaemia | 0 | 0 |
| Cardiac toxicity | 0 | 0 |
| Pneumonitis | 0 | 0 |
| Infection | 0 | 1 (7%) |
| Dry eyes | 0 | 1 (7%) |
| Photophobia | 0 | 0 |
| Blurred vision | 0 | 0 |
| Conjunctivitis | 0 | 0 |
| Corneal ulcer | 0 | 0 |
| Fatigue | 0 | 0 |
| Paronychia | 0 | 0 |
| Epistaxis | 0 | 0 |
| Cystitis | 0 | 0 |
Data are number of patients (%). Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0. No grade 4 or 5 events were reported. Adverse events of grade 1–2 are listed in the appendix. ALT=alanine aminotransferase. AST=aspartate aminotransferase. PPE=palmar-plantar erythrodysaesthesia.
*
Data missing for one patient.